Abstract: Disclosed herein are compounds which exhibit antiviral activity against a plurality of viruses belonging to different families such as Bornaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, and Poxviridae. Thus, methods of preventing, inhibiting, or reducing the viral activity of various viruses are provided as well as methods of treating viral infections.
Type:
Application
Filed:
January 14, 2008
Publication date:
January 8, 2009
Inventors:
Mohammad Javad Aman, Sina Bavari, James C. Burnett, Kelly Lyn Warfield
Abstract: The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.
Type:
Application
Filed:
September 11, 2008
Publication date:
January 1, 2009
Applicant:
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Abstract: The present invention encompasses methods and compositions useful in the diagnosis and treatment of drug resistant leukemia. The invention provides a number of genes that are differentially expressed between drug resistant and drug sensitive acute lymphoblastic leukemia (ALL). These genes act as biomarkers for drug resistant leukemia, and further serve as molecular targets for drugs useful in treating drug resistant leukemia. Accordingly, the invention provides methods of diagnosing drug resistant leukemia and methods of selecting a therapy for subjects affected by drug-resistant leukemia. The invention also provides methods for screening for compounds for treating drug-resistant leukemia, and improved methods for treating drug-resistant leukemia. Compositions of the invention include arrays, computer readable media, and kits for use in the methods of the invention.
Type:
Application
Filed:
May 18, 2005
Publication date:
January 1, 2009
Applicant:
St. Jude Children's Research Hospital
Inventors:
William E. Evans, Robert Pieters, Meyling H. Cheok, Monique L. den Boer, Wenjian Yang
Abstract: This application relates to novel fused tricyclic thienopyridines of Formulas I and II, which useful for treating Hepatitis B infection and other diseases. This application also relates to pharmaceutical compositions comprising thienopyridines and to the use of such compositions to treat Hepatitis B and other diseases.
Type:
Grant
Filed:
February 3, 2006
Date of Patent:
December 16, 2008
Inventors:
Huanming Chen, Robert Tam, Anneke K. Raney
Abstract: Provided herein is a method of protecting a neuron from dysfunction induced by an HIV neurotoxin, comprising contacting the cell with a therapeutically effective dose of a dopamine D1 receptor agonist. Also provided is a method of treating or preventing HIV-1 associated dementia (HAD) in a subject in need of such treatment or prevention, comprising administering to the subject a therapeutically effective dose of a dopamine D1 receptor agonist and estrogenic compound.
Abstract: Compositions and methods are provided for a water-soluble insecticidal or pesticidal comprising at least one alkaloid, particularly at least one tetracyclo-quinolizindine alkaloid derived from sophora roots, particularly matrine and/or oxymatrine.
Abstract: Disclosed herein is a method for preventing ovarian hyperstimulation syndrome in a subject by administering an effective amount of a dopamine agonist in a pharmaceutically acceptable carrier. Also disclosed herein is a method for treating ovarian hyperstimulation syndrome by administering an effective amount of a dopamine agonist in a pharmaceutically acceptable carrier.
Type:
Application
Filed:
April 24, 2006
Publication date:
November 27, 2008
Applicant:
Ferring International Center S.A.
Inventors:
Antonio Pellicer-Martinez, Joan-Carles Arce, Carlos Simon-Valles, Raul Gomez-Gallego
Abstract: The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
Type:
Application
Filed:
August 6, 2008
Publication date:
November 27, 2008
Inventors:
Matthew Abelman, Robert Jiang, Jeff Zablocki, Dmitry Koltun
Abstract: It is demonstrated in the present invention that G-quadruplex ligands can be used to both shorten telomeres and inhibit telomerase by causing telomere uncapping. The invention relates to compositions and methods of treating cancer stem cells comprising the administration of G-quadruplex ligands, such as 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4), which can effectively inhibit or reduce the growth of cancer stem cells. The invention also relates to a synergistic effect in inhibiting or reducing the growth cancer stem cells when a G-quadruplex ligand is combined with a mitotic spindle poison, such as paclitaxel, or other agents used in the treatment of cancer and disease. The invention also relates to RHPS4 inducing non-cancerous cell and non-cancerous stem cell proliferation.
Abstract: The invention provides novel classes of Isoquinoline Derivatives. Pharmaceutical compositions and methods of making and using the compounds, are also described.
Type:
Application
Filed:
June 16, 2008
Publication date:
October 23, 2008
Applicant:
Inotek Pharmaceuticals Corporation
Inventors:
Prakash Jagtap, Erkan Baloglu, John H. van Duzer, Csaba Szabo, Andrew L. Salzman, Aloka Roy, William Williams, Alexander Nivorozhkin
Abstract: This invention relates to solid and stable dispersions of a hydrosoluble derivative of vinca alkaloids in at least one polyethyleneglycol with a molecular mass between 800 and 30,000.
Type:
Application
Filed:
April 14, 2008
Publication date:
October 23, 2008
Applicant:
Pierre Fabre Medicament
Inventors:
Joel Bougaret, Eli LEVERD, Marie-Dominique Ibarra
Abstract: The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
Type:
Grant
Filed:
December 27, 2006
Date of Patent:
October 7, 2008
Assignee:
CV Therapeutics, Inc.
Inventors:
Matthew Abelman, Robert Jiang, Jeff Zablocki, Dmitry Koltun, Melanie Boze
Abstract: Compounds of the formula I, in which s, k, I, W, R1, R2, R3, and U have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.
Type:
Application
Filed:
May 31, 2006
Publication date:
September 11, 2008
Inventors:
Wolfgang Staehle, David Bruge, Kai Schiemann, Dirk Finsinger, Hans-Peter Buchstaller, Frank Zenke, Christiane Amendt
Abstract: The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
Type:
Grant
Filed:
June 28, 2006
Date of Patent:
September 9, 2008
Assignee:
CV Therapeutics, Inc.
Inventors:
Matthew Abelman, Robert Jiang, Jeff Zablocki, Dmitry Koltun
Abstract: Compositions and methods for treating cancer and other hyperproliferatice disease conditions with topoisomerase inhibitors and their prodrugs are disclosed.
Type:
Application
Filed:
November 27, 2005
Publication date:
September 4, 2008
Applicant:
Threshold Pharmaceuticals, Inc.
Inventors:
Mark Matteucci, Jian-Xin Duan, Photon Rao
Abstract: The present invention relates to Dibenzonaphthyridine Derivatives, compositions comprising an effective amount of a Dibenzonaphthyridine Derivative and methods for treating or preventing a proliferative disorder, comprising administering to a subject in need thereof an effective amount of a Dibenzonaphthyridine Derivative.
Type:
Grant
Filed:
December 6, 2006
Date of Patent:
June 17, 2008
Assignee:
Wyeth
Inventors:
Ariamala Gopalsamy, Mengxiao Shi, Kristina Kutterer, Kim Timothy Arndt
Abstract: This invention provides 6H-[1]benzopyrano[4,3-b]quinoline compounds having the formula I: The invention further provides compositions including the compounds, methods for the use of the compounds, and methods of preparation of the compounds.
Abstract: Various calcium channel blockers and pharmaceutical compositions containing these compounds are disclosed. Calcium channel blockers are compounds capable of inhibiting calcium ion channels. Methods for preparing calcium channel blockers and their use as calcium channel antagonists are also disclosed.
Abstract: The instant invention provides for compounds which comprise substituted triazoloquinazolinones that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.
Type:
Application
Filed:
April 24, 2007
Publication date:
November 1, 2007
Inventors:
Kenneth L. Arrington, Edward J. Brnardic, Vadim Y. Dudkin, Mark E. Fraley, Shaei Y. Huang, Cheng Wang
Abstract: The invention provides novel classes of Isoquinoline Derivatives. Pharmaceutical compositions and methods of making and using the compounds, are also described.
Type:
Grant
Filed:
October 12, 2004
Date of Patent:
September 11, 2007
Assignee:
Inotek Pharmaceuticals Corporation
Inventors:
Prakash Jagtap, Csaba Szabo, Andrew L. Salzman, Aloka Roy, William Williams
Abstract: Compounds, compositions and methods are provided that are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. In particular, the compounds of the invention are useful in the treatment and/or prevention of eating disorders, obesity, anxiety disorders and mood disorders.
Type:
Grant
Filed:
November 6, 2003
Date of Patent:
August 7, 2007
Assignee:
Amgen Inc.
Inventors:
Xi Chen, Xiaoqi Chen, Pingchen Fan, Juan Jaen, Leping Li, Jeffrey Thomas Mihalic
Abstract: Mono-ester and asymmetrically substituted diesters of dihydrexidine, dinapsoline and A-86929 and substituted derivatives thereof are described. The novel ester/diester derivatives exhibit improved pharmacokinetic characteristics relative to their unesterified parent compounds and can be formulated into pharmaceutical compositions useful for the treatment of a wide variety of dopamine related disorders.
Abstract: The invention provides compounds of formula I or formula II: wherein: the bond represented by --- is a single bond or a double bond, and R1–R5, X, and Y have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I or II, processes for preparing compounds of formula I or II, intermediates useful for preparing compounds of formula I or II, and therapeutic methods for treating cancer and other topoisomerase related conditions using compounds of formula I or II.
Type:
Grant
Filed:
May 3, 2005
Date of Patent:
April 24, 2007
Assignee:
Rutgers, The State University of New Jersey
Inventors:
Edmond J. LaVoie, Alexander L. Ruchelman, Leroy F. Liu
Abstract: Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds, and processes for the production thereof, pharmaceutical compositions containing these compounds and the use thereof in treatment methods and for the production of pharmaceutical preparations for specific indications, in particular for the treatment of pain.
Type:
Grant
Filed:
February 3, 2004
Date of Patent:
April 3, 2007
Assignee:
Gruenenthal GmbH
Inventors:
Matthias Gerlach, Michael Przewosny, Werner Guenter Englberger, Elke Reissmueller, Petra Bloms-Funke, Corinna Maul, Utz-Peter Jagusch
Abstract: The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by progesterone receptor. Also provided are methods of making such compounds and pharmaceutical compositions.
Type:
Grant
Filed:
October 10, 2003
Date of Patent:
January 16, 2007
Assignee:
Ligand Pharmaceuticals Incorporated
Inventors:
Lin Zhi, Cornelis Arjan Van Oeveren, Bijan Pedram, Donald S. Karanewsky
Abstract: A compound of the formula wherein the substituents are defined as in the specification which compounds are useful in the treatment of cancer.
Type:
Grant
Filed:
August 31, 2004
Date of Patent:
November 14, 2006
Assignee:
Societe de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
Inventors:
Dennis Bigg, Olivier Lavergne, Francesc Pla Rodas, Jacques Pommier, Gérard Ulibarri, Jerry Harnett, Alain Rolland, Anne-Marie Liberatore, Christophe Lanco, Jean-Bernard Cazaux, Christine Le Breton, Eric Manginot
Abstract: The present invention provides compounds having the formula: wherein R1, R2, R, R? and the subscript p are described herein. The compounds are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. Pharmaceutical compositions and methods of using these compounds for the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor, such as eating disorder, obesity, anxiety disorders and mood disorders are also provided.
Type:
Grant
Filed:
August 26, 2004
Date of Patent:
October 24, 2006
Assignee:
Amgen Inc.
Inventors:
Xiaoqi Chen, Pingchen Fan, Juan Jaen, Leping Li, Mike Lizarzaburu, Jeffrey Thomas Mihalic, Stephen Joseph Shuttleworth
Abstract: The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by Progesterone Receptor. Also provided are methods of making such compounds and pharmaceutical compositions.
Abstract: The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by Progesterone Receptor. Also provided are methods of making such compounds and pharmaceutical compositions.
Type:
Grant
Filed:
October 10, 2003
Date of Patent:
July 4, 2006
Assignee:
Ligand Pharmaceuticals Incorporated
Inventors:
Lin Zhi, Cornelis Arjan Van Oeveren, Bijan Pedram, Donald S. Karanewsky
Abstract: The present invention relates to derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and pharmaceutically acceptable salts thereof, use of these compounds as a medicament and for the manufacture of a medicament for treatment of a disease state which can be alleviated by treatment with a 5-HT2B antagonist.
Type:
Grant
Filed:
October 25, 2002
Date of Patent:
June 13, 2006
Assignee:
Biofrontera Bioscience GmbH
Inventors:
Hermann Lubbert, Christoph Ullmer, Emile Bellott, Mark Froimowitz, Douglas Gordon
Abstract: This invention relates to non-steroidal tricyclic compounds that are modulators of androgen receptors and to methods for making and using such compounds.
Type:
Grant
Filed:
February 22, 2002
Date of Patent:
April 11, 2006
Assignee:
Ligand Pharmaceuticals Incorporated
Inventors:
Lin Zhi, Cornelis Arjan Van Oeveren, Jyun-Hung Chen, Robert I. Higuchi
Abstract: This invention relates to a method for selectively enhancing the analgesic potency of a bimodally-acting opioid agonist such as morphine and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of the bimodally-acting opioid agonist. The method of the present invention comprises administering to a subject an analgesic or sub-analgesic amount of a bimodally-acting opioid agonist such as morphine and an amount of an excitatory opioid receptor antagonist such as naltrexone or nalmefene effective to enhance the analgesic potency of the bimodally-acting opioid agonist and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of the bimodally-acting opioid agonist.
Type:
Grant
Filed:
December 13, 2002
Date of Patent:
April 11, 2006
Assignee:
Albert Einstein College of Medicine of Yeshiva University
Abstract: The invention provides compounds of formula I: wherein R1-R9, W, and X have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating cancer and infections using compounds of formula I.
Type:
Grant
Filed:
August 11, 2003
Date of Patent:
January 31, 2006
Assignee:
Rutgers, The University of New Jersey
Inventors:
Edmond J. LaVoie, Alexander L. Ruchelman, Leroy F. Liu
Abstract: The invention provides compounds of formula I: wherein R1–R9, W, and X have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating cancer using compounds of formula I.
Type:
Grant
Filed:
August 11, 2003
Date of Patent:
January 24, 2006
Assignee:
Rutgers, The State University of New Jersey
Inventors:
Edmond J. LaVoie, Sudhir K. Singh, Leroy F. Liu
Abstract: The present invention relates to compounds for the inhibition of poly(ADP-ribose) polymerase (PARP). In some embodiments, the compounds have the Formula: wherein the constituent variables are as defined herein. The invention further provides methods for the use of the compounds disclosed herein.
Abstract: Tetrahydrocarbazoles of formula where Q is —SO2—; —O—; or —(CO)—; X is —(CH)—; or —N—; m is from 1 to 3; t is 0 or 1 and the remaining substituents are as defined herein, are useful as antimicrobial active ingredients.
Type:
Grant
Filed:
September 11, 2001
Date of Patent:
November 22, 2005
Assignee:
Ciba Specialty Chemicals Corporation
Inventors:
Wolfgang Haap, Andreas Mehlin, Karin Petzold, Dietmar Ochs, Werner Hölzl
Abstract: Compounds of formula (I), or pharmaceutically-acceptable salts thereof, are useful in treating inflammatory and immune diseases and disorders, wherein X, Y1, Y2, and R2-4 are as defined in the specification.
Type:
Grant
Filed:
September 27, 2001
Date of Patent:
November 1, 2005
Assignee:
Bristol-Myers Squibb Company
Inventors:
Francis Beaulieu, Carl Quellet, Makonen Belema, Yuping Qiu, Xuejie Yang, Fred C. Zusi
Abstract: Compounds having Formula I are useful for partially or fully antagonizing, repressing, agonizing, or modulating the glucocorticoid receptor and treating immune, autoimmune and inflammatory diseases in a mammal. Also disclosed are pharmaceutical compositions comprising compounds of Formula I and methods of inhibiting immune or autoimmune diseases in a mammal.
Inventors:
Michael J. Coghlan, James P. Edwards, Steven W. Elmore, Todd K. Jones, Michael E. Kort, Philip R. Kym, Jimmie L. Moore, John K. Pratt, Alan X. Wang
Abstract: This invention is concerned with novel polycyclic compounds of formula [I], wherein ring A, ring B, R1, R2, R3, R4, R5, R6, X, Y, R1?, R2?, R3?, R4?, R5?, R6?, ring A?, ring B? and X? are as defined hereinabove as well as pharmaceutically acceptable salts thereof. The compounds have anti-tumor activity and are useful for the treatment of cell proliferative disorders.
Abstract: The invention relates to cerium compounds having general formulas (I) Rni+Yin? and (II) Rb+Yb+ and their application as medicaments in the prophylaxis and/or treatment of cancer diseases.
Type:
Grant
Filed:
February 6, 2004
Date of Patent:
July 26, 2005
Assignee:
Faustus Forschungs Cie. Translational Cancer Research GmbH
Abstract: The present invention relates to the treatment of dopamine-related dysfunction using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, “off-period.” The D1 agonist concentration is reduced during the “off-period” to obtain a plasma concentration of agonist that suboptimally activates D1 dopamine receptors for a period of time to prevent induction of tolerance. Specifically, the method comprises the steps of periodically administering to a patient a full D1 agonist with a half-life of up to about 6 hours at a dose resulting in a first plasma concentration of agonist capable of activating D1 dopamine receptors to produce a therapeutic effect. The dose is reduced at least once every 24 hours to obtain a second lower plasma concentration of agonist that results in suboptimal activation of D1 dopamine receptors for a period of time sufficient to prevent induction of tolerance.
Type:
Grant
Filed:
January 16, 2002
Date of Patent:
July 12, 2005
Assignees:
Purdue Research Foundation, University of North Carolina at Chapel Hill
Inventors:
Richard B. Mailman, David E. Nichols, Xuemei Huang
Abstract: The present invention relates to an improved and economical process for the isolation of anticancer agent Camptothecin from the twigs and stem of Nothapodytes foetida using hot extraction 20(S) Camptothecin is an alkaloid, which contains a pentacyclic ring system that includes a pyrrolo [3,4-b] quinoline moiety (ring A, B and C), the pyridone ring D and a chiral center at C-20 in ring E.
Type:
Grant
Filed:
March 31, 2003
Date of Patent:
May 17, 2005
Assignee:
Council of Scientific and Industrial Research
Inventors:
Santosh Kumar Srivastava, Merajuddin Khan, Suman Preet Singh Khanuja
Abstract: A novel class of tetracyclic compounds represented by the formula I wherein R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, and n are as defined is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
Type:
Grant
Filed:
December 6, 2001
Date of Patent:
March 29, 2005
Assignee:
Eli Lilly and Company
Inventors:
Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer
Abstract: Compounds useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor are provided that have the formula: wherein A and B are CR?; V is either a bond and W is —N(R?)—, or else V is —N(R?)— and W is a bond; Z is —N(R)—CH2—; R1, R2, R3, R4, R?, R?, and R are as defined herein; the subscript n is an integer from 0 to 8; and ?is a benzene ring. Pharmaceutical compositions and methods of using these compounds for the treatment and/or prevention of eating disorders, obesity, anxiety disorders and mood disorders, are also provided.
Type:
Grant
Filed:
May 3, 2002
Date of Patent:
February 22, 2005
Assignee:
Amgen Inc.
Inventors:
Xiaoqi Chen, Kang Dai, Pingchen Fan, Shugui Huang, Leping Li, Jeffrey Thomas Mihalic
Abstract: This invention is directed to compounds of the formula (I): and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions containing such compounds; and methods of using such compounds in the treatment of nicotine addiction/withdrawal and CNS disorders.
Abstract: It has been found that sampangine and related analogs such as benzo[4,5]sampangine, 4-bromosampangine and 4-methoxysampangine may be used as effective fungicidal agents for plants. Fungicidal plant compositions and methods of using the materials for such a purpose are also provided.
Type:
Grant
Filed:
March 27, 2003
Date of Patent:
January 18, 2005
Assignees:
The United States of America as represented by the Secretary of Agriculture, The University of Mississippi